Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction.

[No authors listed]

Osteoporos Int. 1998;8 Suppl 4:S7-80. Review. No abstract available.

PMID:
10197173
2.

Osteoporosis.

Brown SA, Rosen CJ.

Med Clin North Am. 2003 Sep;87(5):1039-63. Review.

PMID:
14621330
3.

Women's health. Osteoporosis.

Metules T.

RN. 2003 Nov;66(11):56-62; quiz 64. Review. No abstract available.

PMID:
14685998
4.

[Primary health care should take the initiative in fighting osteoporosis].

Blivik J.

Lakartidningen. 2002 Feb 28;99(9):876-81. Review. Swedish. No abstract available.

PMID:
11962007
5.
6.

Assessment of the risk of osteoporosis at the menopause: therapeutic consequences.

Raisz LG.

Osteoporos Int. 1994;4 Suppl 1:53-7. Review.

PMID:
8081061
7.

Screening and treatment in the elderly to reduce osteoporotic fracture risk.

Black DM.

Br J Obstet Gynaecol. 1996 May;103 Suppl 13:2-7; discussion 7-8. Review. No abstract available.

PMID:
8624337
8.

[Guidelines for drug therapy of postmenopausal osteoporosis].

Dimai HP, Pietschmann P, Resch H, Leb G, Klaushofer K.

Wien Med Wochenschr. 2002;152(23-24):596-612. Review. German.

PMID:
12530170
9.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
10.

[The value of bone density measurement--a follow-up of the conclusions in the earlier SBU report].

Johnell O, Sääf M.

Lakartidningen. 2000 Sep 20;97(38):4113-6. Review. Swedish.

PMID:
11068375
11.

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.

Kanis JA, Borgstrom F, Johnell O, Jonsson B.

Osteoporos Int. 2004 Nov;15(11):862-71. Epub 2004 Jun 3. Review.

PMID:
15175846
12.
13.

[Alendronate also for women without established osteoporosis?].

Klovning A, Norheim OF.

Tidsskr Nor Laegeforen. 2000 Apr 30;120(11):1347-51. Review. Norwegian. No abstract available.

PMID:
10868100
14.

European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

Osteoporos Int. 2008 Apr;19(4):399-428. doi: 10.1007/s00198-008-0560-z. Epub 2008 Feb 12. Review. Erratum in: Osteoporos Int. 2008 Jul;19(7): 1103-4..

15.

Review of guidelines for bone mineral density testing and treatment of osteoporosis.

Lewiecki EM.

Curr Osteoporos Rep. 2005 Sep;3(3):75-83. Review.

PMID:
16131426
16.

[Pharmaco-economic evaluation of drug therapy osteoporosis. A literature review].

Christensen PM, Brøsen K, Brixen KT, Beck-Nielsen H, Søgaard J, Kristiansen IS.

Ugeskr Laeger. 2002 Mar 4;164(10):1339-45. Review. Danish.

PMID:
11894425
17.

Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option?

Hohenhaus MH, McGarry KA, Col NF.

Drugs. 2007;67(16):2311-21. Review.

PMID:
17983253
18.

Improved strategies for diagnosis and treatment of osteoporosis.

Epstein S, Goodman GR.

Menopause. 1999 Fall;6(3):242-50. Review.

PMID:
10486795
19.

Osteoporosis: evaluation and treatment.

Bajaj S, Saag KG.

Curr Womens Health Rep. 2003 Oct;3(5):418-24. Review.

PMID:
12959702
20.

Hormone replacement therapy in postmenopausal women with end-stage renal disease: a review of the issues.

Holley JL, Schmidt RJ.

Semin Dial. 2001 May-Jun;14(3):146-9. Review.

PMID:
11422914

Supplemental Content

Support Center